Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience
Immunity · 2026
DOI: 10.1016/j.immuni.2026.06.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunity, 2026. Verfasst von Yange Gu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Multi-cell…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Liver Neoplasms, Cholesterol, Carcinoma, Hepatocellular. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China Stem Cell and Translational Research.
Abstract (Originalsprache)
Recurrence after tumor resection and liver transplantation remains a major clinical challenge in hepatocellular carcinoma (HCC). We examined tumor samples from HCC liver transplant patients to identify drivers of disease recurrence. Integration of proteomic profiling of human HCC samples with or without recurrence and T cell killing assays linked the cholesterol esterification enzyme SOAT1 to immune evasion and cancer recurrence. Genetic or pharmacological inhibition of SOAT1 sensitized liver cancer cells to CD8+ T cell-mediated immunosurveillance, anti-programmed cell death 1 (anti-PD-1) therapy, and chimeric antigen receptor (CAR)-T cell therapy and increased intratumoral CD8+ T cell infiltration. Mechanistically, the inhibition of SOAT1-mediated cholesterol esterification disrupted intratumoral cholesterol and lipid metabolism and reduced unsaturated fatty acids and prostaglandin E2 production; this impaired the antioxidant capacity and metabolic resilience of cancer cells under immune attack. Accordingly, SOAT1 inhibition enhanced immunotherapy efficacy in obesity-associated tumors and under immunosuppressant-induced conditions. Thus, cholesterol esterification supports redox fitness and cancer cell resilience upon immune attack, suggesting a strategy to prevent recurrence and improve immunotherapy outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China; Key Laboratory of Multi-cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center…
- Key Laboratory of Multi-cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 20031, China.
- Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Key Laboratory of Multi-cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai 20031, China; University of Chinese Acade…
- Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
- Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute, Fudan University, Shanghai 200040, China.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China Stem Cell and Translational Research
Zitieren
APA
Gu, Y., Zhang, L., Li, J., Ma, E., Hu, W., Liu, Y., Du, X., Zhang, F., Yang, T., Bian, L., Li, W., Jin, Y., Wang, Y., Ning, Z., Yu, C., Li, D., Zhao, J., Xu, C., Wang, Z., & Wang, G. (2026). Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience. Immunity. https://doi.org/10.1016/j.immuni.2026.06.002
Vancouver
Gu Y, Zhang L, Li J, Ma E, Hu W, Liu Y, et al. Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience. Immunity. 2026. doi:10.1016/j.immuni.2026.06.002
BibTeX
@article{Gu2026,
author = {Gu, Yange and Zhang, Lulu and Li, Jianhua and Ma, Ensi and Hu, Weiwei and Liu, Yun and Du, Xiaocheng and Zhang, Feifei and Yang, Tiange and Bian, Linyue and Li, Wenfeng and Jin, Yitian and Wang, Yinghua and Ning, Zihan and Yu, Chune and Li, Dun and Zhao, Jing and Xu, Chenqi and Wang, Zhengxin and Wang, Guangchuan},
title = {Targeting cholesterol esterification sensitizes liver cancer to CD8+ T cell attack by impairing metabolic and redox resilience},
journal = {Immunity},
year = {2026},
doi = {10.1016/j.immuni.2026.06.002}
}
EUVIMED